Adamas to Present at Upcoming HC Wainwright Conference
Adamas Pharmaceuticals (Nasdaq: ADMS) announced that CEO Neil F. McFarlane will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adamas Pharmaceuticals (Nasdaq: ADMS) announced that CEO Neil F. McFarlane will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15 at 12:30 pm ET. The presentation will be available via live webcast on the company's investor relations webpage, with a replay accessible for 30 days post-event. Adamas focuses on developing innovative therapies for neurological diseases, having launched GOCOVRI®, the first FDA-approved treatment for dyskinesia in Parkinson’s patients, in 2018.
Details
News Market Reaction – ADMS
The recorded move for ADMS in the trading session of this news was +2.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15th at 12:30 pm Eastern Time (9:30 am Pacific).
The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. An archived version of the webcast will be available via replay for 30 days following the presentation.
About Adamas Pharmaceuticals, Inc.
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit www.adamaspharma.com.
Contact:
Investors:
Peter Vozzo
Managing Director, Westwicke
443-213-0505
peter.vozzo@westwicke.com
Media:
Sarah Mathieson
Vice President of Corporate Communications
510-450-3528
smathieson@adamaspharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.